Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Feb;102(2):e47-e51.
doi: 10.3324/haematol.2016.153130. Epub 2016 Oct 27.

Low-dose Clofarabine in Combination With a Standard Remission Induction in Patients Aged 18-60 Years With Previously Untreated Intermediate and Bad-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: Combined Phase I/II Results of the EORTC/GIMEMA AML-14A Trial

Affiliations
Free PMC article
Clinical Trial

Low-dose Clofarabine in Combination With a Standard Remission Induction in Patients Aged 18-60 Years With Previously Untreated Intermediate and Bad-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: Combined Phase I/II Results of the EORTC/GIMEMA AML-14A Trial

Dominik Selleslag et al. Haematologica. .
Free PMC article

Figures

Figure 1.
Figure 1.
Overall survival (A), relapse-free survival from complete remission (CR) (B), cumulative incidence of relapse from CR (C) and cumulative incidence of death in CR (D) in the two arms.

Similar articles

See all similar articles

Cited by 1 article

MeSH terms

Feedback